Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Frizzell

Physician Assistant, Medical Paducah, KY Physician Assistant

NPI 1306036603 CMS profile 10443468

100 Kiana Court, Suite B, Paducah, KY 42001

Open in the dashboard

General payments

$10,311

568 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Frizzell of Paducah, KY is reported in the CMS Open Payments database as having received $10,311 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,977 100
2024 General $2,083 100
2023 General $2,051 116
2022 General $2,230 129
2021 General $1,970 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Frizzell
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jessica Frizzell were reported at $1,977. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jessica Frizzell Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,970 $156 $41–$563 $132
2022 $2,230 $185 $55–$649 $149
2023 $2,051 $199 $58–$717 $160
2024 $2,083 $206 $62–$740 $164
2025 $1,977 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,232 131 payments
  2. AbbVie, Inc. $1,884 114 payments
  3. UCB, Inc. $1,244 76 payments
  4. Janssen Biotech, Inc. $1,085 52 payments
  5. Novartis Pharmaceuticals Corporation $580 34 payments
  6. Horizon Therapeutics plc $453 31 payments
  7. Lilly USA, LLC $319 16 payments
  8. Medtronic, Inc. $304 2 payments
  9. Pfizer Inc. $251 13 payments
  10. Mallinckrodt Hospital Products Inc. $209 8 payments
  11. Other $1,749 91 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,012 563 payments
  2. Education $299 5 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,394 87 payments
  2. Cimzia $1,013 65 payments
  3. TREMFYA $800 36 payments
  4. Otezla $583 32 payments
  5. Enbrel Inflammation $489 28 payments
  6. Enbrel Inflammation $469 24 payments
  7. Prolia $396 24 payments
  8. EVENITY $385 24 payments
  9. TAVNEOS $369 21 payments
  10. KRYSTEXXA $333 24 payments
  11. Other $5,997 312 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,925

Median for Physician Assistant: 241

Drug cost

$243,725

Median for Physician Assistant: $4,110

Branded share of claims

18.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $104,853
Enbrel Sureclick Etanercept Brand 13 $92,355
Hydroxychloroquine Sulfate Generic 346 $12,397
Leflunomide Generic 122 $9,178
Methotrexate Methotrexate Sodium Brand 296 $6,885
Colchicine Generic 67 $3,995
Duloxetine Hcl Generic 185 $2,347
Celecoxib Generic 99 $2,221
Prednisone Generic 320 $1,927
Diclofenac Sodium Generic 63 $1,641

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$880,201

Of which drugs: $777,829

Medicare patients

707

Average age 72

Services billed

91,368

508 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 29%
Chronic kidney disease 27%
Ischemic heart disease 25%
COPD 25%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 66 69,600 $250,678
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 31 6,100 $206,990
Injection, denosumab, 1 mg J0897 Office 39 2,400 $48,475
Injection, golimumab, 1 mg, for intravenous use J1602 Office 17 3,450 $31,116
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 103 912 $641
Injection, hydrocortisone sodium succinate, up to 100 mg J1720 Office 22 34 $501

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $176
$176 — —
Enbrel
  • Amgen Inc. $146
$146 13 —
Cimzia
  • UCB, Inc. $125
$125 — 69,600
TREMFYA
  • Janssen Biotech, Inc. $124
$124 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record